{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:36:07Z","timestamp":1789662967241,"version":"4.0.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11906-025-01342-7","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T13:47:30Z","timestamp":1764596850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists"],"prefix":"10.1007","volume":"27","author":[{"given":"Ahmed Kamal","family":"Siddiqi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandita","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"1342_CR1","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","volume":"392","author":"JD Stanaway","year":"2018","unstructured":"Stanaway JD, et al. Global, regional, and National comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1923\u201394.","journal-title":"Lancet"},{"key":"1342_CR2","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","volume":"392","author":"GBD 2017 Causes of Death Collaborators","year":"2018","unstructured":"GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1736\u201388.","journal-title":"Lancet"},{"issue":"10258","key":"1342_CR3","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"GBD 2019 Risk Factors Collaborators","year":"2020","unstructured":"GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1223\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(20)30752-2.","journal-title":"Lancet"},{"key":"1342_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441\u201350.","journal-title":"Circulation"},{"issue":"Suppl 2","key":"1342_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/ckj\/sfae296","volume":"17","author":"D Abasheva","year":"2024","unstructured":"Abasheva D, Ortiz A, Fernandez-Fernandez B. GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity. Clin Kidney J. 2024;17(Suppl 2):19\u201335. https:\/\/doi.org\/10.1093\/ckj\/sfae296.","journal-title":"Clin Kidney J"},{"issue":"10022","key":"1342_CR6","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(15)01225-8.","journal-title":"Lancet"},{"key":"1342_CR7","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"Blood Pressure Lowering Treatment Trialists C","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists C. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625\u201336.","journal-title":"Lancet"},{"issue":"7","key":"1342_CR8","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1161\/CIRCRESAHA.121.318083","volume":"128","author":"RM Carey","year":"2021","unstructured":"Carey RM, Wright JT Jr, Taler SJ, Whelton PK. Guideline-driven management of hypertension: an evidence-based update. Circ Res. 2021;128(7):827\u201346. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318083.","journal-title":"Circ Res"},{"issue":"8","key":"1342_CR9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1751-7176.2008.08172.x","volume":"10","author":"RE Schmieder","year":"2008","unstructured":"Schmieder RE, Ruilope LM. Blood pressure control in patients with comorbidities. J Clin Hypertens (Greenwich). 2008;10(8):624\u201331. https:\/\/doi.org\/10.1111\/j.1751-7176.2008.08172.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1342_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrcardio.2011.157","volume":"9","author":"L Ruilope","year":"2012","unstructured":"Ruilope L. Current challenges in the clinical management of hypertension. Nat Rev Cardiol. 2012;9:267\u201375. https:\/\/doi.org\/10.1038\/nrcardio.2011.157.","journal-title":"Nat Rev Cardiol"},{"key":"1342_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11906-015-0621-6","volume":"18","author":"A Goud","year":"2016","unstructured":"Goud A, Zhong J, Peters M, et al. GLP-1 agonists and blood pressure: a review of the evidence. Curr Hypertens Rep. 2016;18:16. https:\/\/doi.org\/10.1007\/s11906-015-0621-6.","journal-title":"Curr Hypertens Rep"},{"key":"1342_CR12","doi-asserted-by":"publisher","first-page":"102789","DOI":"10.1016\/j.eclinm.2024.102789","volume":"75","author":"C Jarade","year":"2024","unstructured":"Jarade C, Zolotarova T, Moiz A, Eisenberg MJ. GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review. EClinicalMedicine. 2024;75:102789. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102789. PMID: 39246720; PMCID: PMC11377134.","journal-title":"EClinicalMedicine"},{"key":"1342_CR13","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925\u201366.","journal-title":"Diabetologia"},{"key":"1342_CR14","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41440-021-00665-7","volume":"44","author":"A Tanaka","year":"2021","unstructured":"Tanaka A, Node K. Hypertension in diabetes care: emerging roles of recent hypoglycemic agents. Hypertens Res. 2021;44:897\u2013905.","journal-title":"Hypertens Res"},{"issue":"4","key":"1342_CR15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2337\/dc18-2207","volume":"42","author":"PI Georgianos","year":"2019","unstructured":"Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care. 2019;42(4):693\u2013700.","journal-title":"Diabetes Care"},{"issue":"8","key":"1342_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/dom.12085","volume":"15","author":"B Wang","year":"2013","unstructured":"Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab Ao\u00fbt. 2013;15(8):737\u201349.","journal-title":"Diabetes Obes Metab Ao\u00fbt"},{"issue":"2","key":"1342_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40256-020-00423-z","volume":"21","author":"CI Liakos","year":"2021","unstructured":"Liakos CI, Papadopoulos DP, Sanidas EA, Markou MI, Hatziagelaki EE, Grassos CA, et al. Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors). Am J Cardiovasc Drugs Mars. 2021;21(2):123\u201337.","journal-title":"Am J Cardiovasc Drugs Mars"},{"issue":"10","key":"1342_CR18","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021887.","journal-title":"Circulation"},{"issue":"2","key":"1342_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11906-019-0920-4","volume":"21","author":"H Sternlicht","year":"2019","unstructured":"Sternlicht H, Bakris GL. Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): more than osmotic diuresis. Curr Hypertens Rep. 2019;21(2):12. https:\/\/doi.org\/10.1007\/s11906-019-0920-4.","journal-title":"Curr Hypertens Rep"},{"issue":"9","key":"1342_CR20","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","volume":"136","author":"MA Nauck","year":"2017","unstructured":"Nauck MA, Meier JJ, Cavender MA, et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136(9):849\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028136.","journal-title":"Circulation"},{"key":"1342_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12933-023-01797-5","volume":"22","author":"I Lingvay","year":"2023","unstructured":"Lingvay I, Mosenzon O, Brown K, et al. Systolic blood pressure reduction with Tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc Diabetol. 2023;22:66. https:\/\/doi.org\/10.1186\/s12933-023-01797-5.","journal-title":"Cardiovasc Diabetol"},{"issue":"18","key":"1342_CR22","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e895-1032.","journal-title":"Circulation"},{"issue":"10296","key":"1342_CR23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink H, Cuthbertson DJ, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398(10296):262\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(21)00536-5.","journal-title":"Lancet"},{"key":"1342_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/14017431.2024.2418086","author":"SK Kunutsor","year":"2024","unstructured":"Kunutsor SK, Seidu S, Dey RS, Baidoo IK, Oulhaj A. Cardiovascular and kidney benefits of SGLT-2is and GLP-1RAs according to baseline blood pressure in type 2 diabetes: a systematic meta-analysis of cardiovascular outcome trials. Scand Cardiovasc J. 2024. https:\/\/doi.org\/10.1080\/14017431.2024.2418086.","journal-title":"Scand Cardiovasc J"},{"issue":"6","key":"1342_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.hjc.2018.11.008","volume":"60","author":"E Andrikou","year":"2019","unstructured":"Andrikou E, Tsioufis C, Andrikou I, et al. GLP-1 receptor agonists and cardiovascular outcome trials: an update. Hellenic J Cardiol. 2019;60(6):347\u201351. https:\/\/doi.org\/10.1016\/j.hjc.2018.11.008.","journal-title":"Hellenic J Cardiol"},{"key":"1342_CR26","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice C. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45:S144\u2013S174.","DOI":"10.2337\/dc22-S010"},{"issue":"6","key":"1342_CR27","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2337\/dc22-0772","volume":"46","author":"JM Rodriguez-Valadez","year":"2023","unstructured":"Rodriguez-Valadez JM, Tahsin M, Fleischmann KE, et al. Cardiovascular and renal benefits of novel diabetes drugs by baseline cardiovascular risk: a systematic review, meta-analysis, and meta-regression. Diabetes Care. 2023;46(6):1300\u201310. https:\/\/doi.org\/10.2337\/dc22-0772.","journal-title":"Diabetes Care"},{"issue":"10","key":"1342_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s11886-019-1219-4","volume":"21","author":"C Wojcik","year":"2019","unstructured":"Wojcik C, Warden BA. Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors. Curr Cardiol Rep. 2019;21(10):130. https:\/\/doi.org\/10.1007\/s11886-019-1219-4.","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"1342_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","volume":"32","author":"EC Chao","year":"2014","unstructured":"Chao EC. SGLT-2 inhibitors: a new mechanism for glycemic control. Clin Diabetes. 2014;32(1):4\u201311. https:\/\/doi.org\/10.2337\/diaclin.32.1.4.","journal-title":"Clin Diabetes"},{"issue":"2","key":"1342_CR30","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14360","volume":"8","author":"T Masuda","year":"2020","unstructured":"Masuda T, Muto S, Fukuda K, et al. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume. Physiol Rep. 2020;8(2):e14360. https:\/\/doi.org\/10.14814\/phy2.14360.","journal-title":"Physiol Rep"},{"issue":"6","key":"1342_CR31","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/hr.2016.1","volume":"39","author":"K Tamura","year":"2016","unstructured":"Tamura K, Wakui H, Azushima K, et al. Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of type 2 diabetes. Hypertens Res. 2016;39(6):396\u20138. https:\/\/doi.org\/10.1038\/hr.2016.1.","journal-title":"Hypertens Res"},{"issue":"12","key":"1342_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrneph.2016.145","volume":"12","author":"F Artunc","year":"2016","unstructured":"Artunc F, Schleicher E, Weigert C, et al. The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol. 2016;12(12):721\u201337. https:\/\/doi.org\/10.1038\/nrneph.2016.145.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"1342_CR33","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00125-015-3547-2","volume":"58","author":"WT Cefalu","year":"2015","unstructured":"Cefalu WT, Stenl\u00f6f K, Leiter LA, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58(6):1183\u20137. https:\/\/doi.org\/10.1007\/s00125-015-3547-2.","journal-title":"Diabetologia"},{"key":"1342_CR34","doi-asserted-by":"publisher","first-page":"105108","DOI":"10.1016\/j.phrs.2020.105108","volume":"161","author":"I Ilias","year":"2020","unstructured":"Ilias I, Thomopoulos C, Michalopoulou H, Bazoukis G, Tsioufis C, Makris T. Antidiabetic drugs and blood pressure changes. Pharmacol Res. 2020;161:105108. https:\/\/doi.org\/10.1016\/j.phrs.2020.105108.","journal-title":"Pharmacol Res"},{"issue":"1","key":"1342_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/CD9.0000000000000114","volume":"4","author":"M Tadic","year":"2024","unstructured":"Tadic M, Cuspidi C. Antihypertensive effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Cardiology Discovery. 2024;4(1):38\u201342. https:\/\/doi.org\/10.1097\/CD9.0000000000000114.","journal-title":"Cardiology Discovery"},{"issue":"22","key":"1342_CR36","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"3","key":"1342_CR37","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420\u20138. https:\/\/doi.org\/10.2337\/dc14-1096.","journal-title":"Diabetes Care"},{"issue":"6","key":"1342_CR38","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.116.07703","volume":"68","author":"G Mancia","year":"2016","unstructured":"Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, Broedl UC, Johansen OE. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension. 2016;68(6):1355\u201364. Epub 2016 Oct 10. PMID: 27977392.","journal-title":"Hypertension"},{"issue":"18","key":"1342_CR39","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1161\/CIRCULATIONAHA.118.036568","volume":"139","author":"KC Ferdinand","year":"2019","unstructured":"Ferdinand KC, Izzo JL, Lee J, Meng L, George J, Salsali A, et al. Antihyperglycemic and blood pressure effects of empagliflozin in Black patients with type 2 diabetes mellitus and hypertension. Circulation. 2019;139(18):2098\u2013109. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.036568.","journal-title":"Circulation"},{"issue":"18","key":"1342_CR40","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","volume":"139","author":"K Kario","year":"2019","unstructured":"Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al. Twenty-four-hour blood pressure-lowering effect of a Sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation. 2019;139(18):2089\u201397. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037076.","journal-title":"Circulation"},{"issue":"2","key":"1342_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"EMPA-KIDNEY The","year":"2023","unstructured":"The EMPA-KIDNEY, Collaborative G, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"12","key":"1342_CR42","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/ajh\/hpaa073","volume":"33","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Fitchett D, Ofstad AP, Kraus BJ, Wanner C, Zwiener I, et al. Empagliflozin for patients with presumed resistant hypertension: a post hoc analysis of the EMPA-REG OUTCOME trial. Am J Hypertens. 2020;33(12):1092\u2013101. https:\/\/doi.org\/10.1093\/ajh\/hpaa073.","journal-title":"Am J Hypertens"},{"key":"1342_CR43","doi-asserted-by":"publisher","first-page":"ehae938","DOI":"10.1093\/eurheartj\/ehae938","volume":"4","author":"M B\u00f6hm","year":"2025","unstructured":"B\u00f6hm M, Butler J, Coats A, Lauder L, Mahfoud F, Filippatos G, Ferreira JP, Pocock SJ, Brueckmann M, Hauske SJ, Schueler E, Wanner C, Verma S, Zannad F, Packer M, Anker SD. Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur Heart J 2025. 2025;4:ehae938. https:\/\/doi.org\/10.1093\/eurheartj\/ehae938.","journal-title":"Eur Heart J 2025"},{"issue":"4","key":"1342_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"issue":"14","key":"1342_CR45","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353\u201368. https:\/\/doi.org\/10.1001\/jama.2020.1906.","journal-title":"JAMA"},{"issue":"21","key":"1342_CR46","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1161\/CIRCULATIONAHA.121.058103","volume":"145","author":"R Furtado","year":"2022","unstructured":"Furtado R, Raz I, Goodrich EL, et al. Efficacy and safety of Dapagliflozin in type 2 diabetes according to baseline blood pressure: observations from DECLARE-TIMI 58 trial. Circulation. 2022;145(21):1581\u201391. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.058103.","journal-title":"Circulation"},{"issue":"2","key":"1342_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3109\/08037051.2015.1116258","volume":"25","author":"MA Weber","year":"2016","unstructured":"Weber MA, Mansfield TA, Alessi F, Iqbal N, Parikh S, Ptaszynska A. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. Blood Press. 2016;25(2):93\u2013103. https:\/\/doi.org\/10.3109\/08037051.2015.1116258.","journal-title":"Blood Press"},{"issue":"3","key":"1342_CR48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","volume":"4","author":"MA Weber","year":"2016","unstructured":"Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4(3):211\u201320. https:\/\/doi.org\/10.1016\/S2213-8587(15)00417-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1342_CR49","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1177\/1479164115585298","volume":"12","author":"CD Sj\u00f6str\u00f6m","year":"2015","unstructured":"Sj\u00f6str\u00f6m CD, Johansson P, Ptaszynska A, List J, Johnsson E. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab Vasc Dis Res. 2015;12(5):352\u20138. https:\/\/doi.org\/10.1177\/1479164115585298.","journal-title":"Diab Vasc Dis Res"},{"issue":"9733","key":"1342_CR50","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(10)60407-2.","journal-title":"Lancet"},{"issue":"24","key":"1342_CR51","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.123.065254","volume":"148","author":"JW Ostrominski","year":"2023","unstructured":"Ostrominski JW, Vaduganathan M, Selvaraj S, Claggett BL, Miao ZM, Desai AS, Jhund PS, Kosiborod MN, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Hernandez AF, Shah SJ, Petersson M, Maria Langkilde A, McMurray JJV, Solomon SD. Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. Circulation. 2023;148(24):1945\u201357. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065254.","journal-title":"Circulation"},{"issue":"4","key":"1342_CR52","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","volume":"137","author":"KW Mahaffey","year":"2018","unstructured":"Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study). Circulation. 2018;137(4):323\u201334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032038.","journal-title":"Circulation"},{"issue":"24","key":"1342_CR53","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"1","key":"1342_CR54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/jch.12747","volume":"18","author":"RR Townsend","year":"2016","unstructured":"Townsend RR, Machin I, Ren J, Trujillo A, Kawaguchi M, Vijapurkar U, Damaraju CV, Pfeifer M. Reductions in mean 24-Hour ambulatory blood pressure after 6-Week treatment with Canagliflozin in patients with type 2 diabetes mellitus and hypertension. J Clin Hypertens (Greenwich). 2016;18(1):43\u201352.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"12","key":"1342_CR55","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/jch.12425","volume":"16","author":"MR Weir","year":"2014","unstructured":"Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014;16(12):875\u201382. https:\/\/doi.org\/10.1111\/jch.12425.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"1342_CR56","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.2337\/dc11-1926","volume":"35","author":"J Rosenstock","year":"2012","unstructured":"Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W, Canagliflozin, DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to Metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232\u20138. Epub 2012 Apr 9. PMID: 22492586; PMCID: PMC3357223.","journal-title":"Diabetes Care"},{"issue":"1","key":"1342_CR57","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12933-019-0856-7","volume":"18","author":"J Liu","year":"2019","unstructured":"Liu J, Pong A, Gallo S, Darekar A, Terra SG. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. Cardiovasc Diabetol. 2019;18(1):59. https:\/\/doi.org\/10.1186\/s12933-019-0856-7.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"1342_CR58","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1111\/dom.13394","volume":"20","author":"KA Han","year":"2018","unstructured":"Han KA, Chon S, Chung CH, Lim S, Lee KW, Baik S, et al. Efficacy and safety of Ipragliflozin as an add-on therapy to sitagliptin and Metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: a randomized controlled trial. Diabetes Obes Metab. 2018;20(10):2408\u201315. https:\/\/doi.org\/10.1111\/dom.13394.","journal-title":"Diabetes Obes Metab"},{"key":"1342_CR59","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1475-2840-13-65","volume":"13","author":"K Kaku","year":"2014","unstructured":"Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, Watanabe D, Tofogliflozin 003 Study Group. Efficacy and safety of monotherapy with the novel sodium\/glucose cotransporter-2 inhibitor Tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65. https:\/\/doi.org\/10.1186\/1475-2840-13-65. PMID: 24678906; PMCID: PMC4021346.","journal-title":"Cardiovasc Diabetol"},{"issue":"19","key":"1342_CR60","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"9","key":"1342_CR61","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1901118.","journal-title":"N Engl J Med"},{"issue":"11","key":"1342_CR62","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"24","key":"1342_CR63","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"1","key":"1342_CR64","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12933-022-01555-z","volume":"21","author":"T Davis","year":"2022","unstructured":"Davis T, Giczewska A, Lokhnygina Y, et al. Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the exenatide study of cardiovascular event Lowering (EXSCEL). Cardiovasc Diabetol. 2022;21(1):116. https:\/\/doi.org\/10.1186\/s12933-022-01555-z.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1342_CR65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3810\/pgm.2013.05.2660","volume":"125","author":"M Grimm","year":"2013","unstructured":"Grimm M, Han J, Weaver C, et al. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. Postgrad Med. 2013;125(3):47\u201357. https:\/\/doi.org\/10.3810\/pgm.2013.05.2660.","journal-title":"Postgrad Med"},{"issue":"3","key":"1342_CR66","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/ajh.2009.245","volume":"23","author":"T Okerson","year":"2010","unstructured":"Okerson T, Yan P, Stonehouse A, et al. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2010;23(3):334\u20139. https:\/\/doi.org\/10.1038\/ajh.2009.245.","journal-title":"Am J Hypertens"},{"issue":"12","key":"1342_CR67","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"JP Fr\u00edas","year":"2016","unstructured":"Fr\u00edas JP, Guja C, Hardy E, et al. Exenatide once weekly plus Dapagliflozin once daily versus exenatide or Dapagliflozin alone in patients with type 2 diabetes inadequately controlled with Metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004\u201316. https:\/\/doi.org\/10.1016\/S2213-8587(16)30267-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1342_CR68","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"10","key":"1342_CR69","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","volume":"52","author":"D Russell-Jones","year":"2009","unstructured":"Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046\u201355. https:\/\/doi.org\/10.1007\/s00125-009-1472-y.","journal-title":"Diabetologia"},{"issue":"7","key":"1342_CR70","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes. JAMA. 2015;314(7):687 Large weight loss trial with liraglutide that demonstrates BP (clinic BP) lowering with liraglutide administration. There was also an increase in heart rate noted. A variety of surrogate measures such as hs-CRP, fibrinogen and PAI-1 were favorably modulated.","journal-title":"JAMA"},{"issue":"3","key":"1342_CR71","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"issue":"4","key":"1342_CR72","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","volume":"81","author":"JA de Lemos","year":"2024","unstructured":"de Lemos JA, Linetzky B, le Roux CW, Laffin LJ, Vongpatanasin W, Fan L, Hemmingway A, Ahmad NN, Bunck MC, Stefanski A. Tirzepatide reduces 24-Hour ambulatory blood pressure in adults with body mass index \u2265 27 kg\/m2: SURMOUNT-1 ambulatory blood pressure monitoring substudy. Hypertension. 2024;81(4):e41-3.","journal-title":"Hypertension"},{"issue":"12","key":"1342_CR73","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/ajh\/hpaa100","volume":"33","author":"KC Tran","year":"2020","unstructured":"Tran KC, Hiremath S. SGLT2 inhibitors in resistant hypertension: a sweet solution. Am J Hypertens. 2020;33(12):1071\u20134. https:\/\/doi.org\/10.1093\/ajh\/hpaa100.","journal-title":"Am J Hypertens"},{"issue":"2","key":"1342_CR74","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002343","volume":"5","author":"RE Schmieder","year":"2016","unstructured":"Schmieder RE, Ott C, Schmid A, Friedrich S, Kistner I, Ditting T, et al. Adherence to antihypertensive medication in treatment-resistant hypertension undergoing renal denervation. J Am Heart Assoc. 2016;5(2):e002343. https:\/\/doi.org\/10.1161\/JAHA.115.002343.","journal-title":"J Am Heart Assoc"},{"key":"1342_CR75","doi-asserted-by":"publisher","unstructured":"Diaconu CC, Cozma MA, Dobric\u0103 EC, Gheorghe G, Jichitu A, Ionescu VA, Nicolae AC, Dr\u0103goi CM, G\u0103man MA. Polypharmacy in the management of arterial hypertension-friend or foe?? Medicina (Kaunas). 2021;57(12). https:\/\/doi.org\/10.3390\/medicina57121288.","DOI":"10.3390\/medicina57121288"},{"issue":"11","key":"1342_CR76","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","volume":"142","author":"M Griffin","year":"2020","unstructured":"Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, Butler J, Inzucchi SE, Testani JM. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020;142(11):1028\u201339. Epub 2020 May 15. PMID: 32410463; PMCID: PMC7521417.","journal-title":"Circulation"},{"issue":"3","key":"1342_CR77","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.xkme.2020.01.010","volume":"2","author":"EC Ray","year":"2020","unstructured":"Ray EC, Boyd-Shiwarski CR, Liu P, Novacic D, Cassiman D. SGLT2 inhibitors for treatment of refractory hypomagnesemia: a case report of 3 patients. Kidney Med. 2020;2(3):359\u201364. https:\/\/doi.org\/10.1016\/j.xkme.2020.01.010.","journal-title":"Kidney Med"},{"issue":"5","key":"1342_CR78","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/oby.24002","volume":"32","author":"XH Pan","year":"2024","unstructured":"Pan XH, Tan B, Chin YH, Lee ECZ, Kong G, Chong B, Kueh M, Khoo CM, Mehta A, Majety P, Grandhi GR, Dimitriadis GK, Foo R, Chew NWS, Le Roux CW, Mamas MA, Chan MY. Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. Obes (Silver Spring). 2024;32(5):840\u201356. https:\/\/doi.org\/10.1002\/oby.24002. Epub 2024 Feb 27. PMID: 38413012.","journal-title":"Obes (Silver Spring)"},{"key":"1342_CR79","unstructured":"FDA approves weight management drug for patients aged 12 and older.U.S. Food & Drug Administration, 2020 Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-weight-management-drug-patients-aged-12-and-older"},{"key":"1342_CR80","unstructured":"Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551568\/"},{"issue":"2","key":"1342_CR81","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/dom.14890","volume":"25","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Bhatta M, Davies M, Deanfield JE, Garvey WT, Khalid U, Kushner R, Rubino DM, Zeuthen N, Verma S. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023;25(2):468\u201378.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1342_CR82","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.117.032130","volume":"137","author":"CA Schiavon","year":"2018","unstructured":"Schiavon CA, Bersch-Ferreira AC, Santucci EV, Oliveira JD, Torreglosa CR, Bueno PT, et al. Effects of bariatric surgery in obese patients with hypertension: the GATEWAY randomized trial (gastric bypass to treat obese patients with steady hypertension). Circulation. 2018;137(11):1132\u201342. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032130.","journal-title":"Circulation"},{"key":"1342_CR83","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004007","volume":"6","author":"M Mazidi","year":"2017","unstructured":"Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6:e00407.","journal-title":"J Am Heart Assoc"},{"issue":"262\u2013275","key":"1342_CR84","first-page":"e9","volume":"8","author":"WL Baker","year":"2014","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(262\u2013275):e9.","journal-title":"J Am Soc Hypertens"},{"key":"1342_CR85","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/dom.12307","volume":"16","author":"A Liakos","year":"2014","unstructured":"Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984\u201393.","journal-title":"Diabetes Obes Metab"},{"key":"1342_CR86","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005686","volume":"6","author":"WL Baker","year":"2017","unstructured":"Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, et al. Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6:e005686.","journal-title":"J Am Heart Assoc"},{"key":"1342_CR87","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/ajh\/hpt196","volume":"27","author":"M Katout","year":"2014","unstructured":"Katout M, Zhu H, Rutsky J, Shah P, Brook RD, Zhong J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2014;27:130\u20139.","journal-title":"Am J Hypertens"},{"key":"1342_CR88","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.114.03062","volume":"64","author":"KC Ferdinand","year":"2014","unstructured":"Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64:731\u20137.","journal-title":"Hypertension"},{"key":"1342_CR89","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","volume":"110","author":"F Sun","year":"2015","unstructured":"Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110:26\u201337.","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"1342_CR90","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/ijcp.12698","volume":"69","author":"WJ Saulsberry","year":"2015","unstructured":"Saulsberry WJ, Coleman CI, Mearns ES, Zaccaro E, Doleh Y, Sobieraj DM. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. Int J Clin Pract. 2015;69(11):1221\u201335. https:\/\/doi.org\/10.1111\/ijcp.12698.","journal-title":"Int J Clin Pract"},{"issue":"5","key":"1342_CR91","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1185\/03007995.2015.1135110","volume":"32","author":"G Lozano-Ortega","year":"2016","unstructured":"Lozano-Ortega G, Goring S, Bennett HA, Bergenheim K, Sternhufvud C, Mukherjee J. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with Metformin plus sulfonylurea. Curr Med Res Opin. 2016;32(5):807\u201316. Epub 2016 Feb 29. PMID: 26700585.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1342_CR92","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, et al. How does empagliflozin reduce cardiovascular mortality?? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(2):356\u201363. https:\/\/doi.org\/10.2337\/dc17-1096.","journal-title":"Diabetes Care"},{"issue":"5","key":"1342_CR93","doi-asserted-by":"publisher","DOI":"10.1177\/1479164120953625","volume":"17","author":"X Rong","year":"2020","unstructured":"Rong X, Li X, Gou Q, Liu K, Chen X. Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials. Diab Vasc Dis Res. 2020;17(5):1479164120953625. https:\/\/doi.org\/10.1177\/1479164120953625.","journal-title":"Diab Vasc Dis Res"},{"issue":"8","key":"1342_CR94","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1111\/dom.15631","volume":"26","author":"KL Jones","year":"2024","unstructured":"Jones KL, Marathe CS, Wu T, Rayner CK, Nauck M, Horowitz M. Getting the measure of the pressure: optimal assessment of the effects of glucagon-like peptide-1 receptor agonists on blood pressure. Diabetes Obes Metab. 2024;26(8):3003\u20135. https:\/\/doi.org\/10.1111\/dom.15631.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1342_CR95","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/j.amepre.2017.06.020","volume":"53","author":"C Park","year":"2017","unstructured":"Park C, et al. Cost-effectiveness analyses of antihypertensive medicines: A systematic review. Am J Prev Medicinevol. 2017;53(2):S131\u201342. https:\/\/doi.org\/10.1016\/j.amepre.2017.06.020.","journal-title":"Am J Prev Medicinevol"},{"key":"1342_CR96","doi-asserted-by":"publisher","unstructured":"Luo J, et al. Evaluation of Out-of-Pocket costs and treatment intensification with an SGLT2 inhibitor or GLP-1 RA in patients with type 2 diabetes and cardiovascular disease. JAMA Netw Open Vol. Jun. 2023;6(1). https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.17886. 6 e2317886.","DOI":"10.1001\/jamanetworkopen.2023.17886"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-025-01342-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-025-01342-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-025-01342-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:02:27Z","timestamp":1770476547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-025-01342-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1342"],"URL":"https:\/\/doi.org\/10.1007\/s11906-025-01342-7","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"28"}}